Clinical Trial Update: Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study assessing within-subject variability of ER torsemide 20 mg tablets in healthy subjects, sponsored by Sarfez Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure

Drugs mentioned

• ER Torsemide 20 mg Tablet (torsemide)

Snippet

Sponsor: Sarfez Pharmaceuticals, Inc. | Conditions: Congestive Heart Failure, Chronic Kidney Diseases | Phase 1 | Status: COMPLETED